Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class.[1] It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).
Clinical data | |
---|---|
Trade names | Glurenorm |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral (tablets) |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High (Tmax = 2–3 hours) |
Metabolism | Extensive hepatic |
Onset of action | 1–1.5 hours |
Excretion | Biliary (95%), renal (5%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.046.770 |
Chemical and physical data | |
Formula | C27H33N3O6S |
Molar mass | 527.64 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |
Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease and diabetic nephropathy.[2]